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Background: As  live kidney donation rates increase, understanding the outcomes and risks 
for donors  is increasingly important. Aim of this study was to investigate all-cause mortality plus 
long-term morbidity outcomes of live kidney donors compared with healthy cohort.    
Methods:Datasets were obtained from UK Transplant Registry and a comparator non-donor 
cohort selected from The Health Improvement Network (THIN) database, a UK primary health 
care database.  All live kidney donors(LD) from 1stJanuary 2001 to 31stDecember, 2013 were 
included, with follow-up until 31st  December 2016. 
Results: There were 9750 LD and 27000 THIN participants. Median follow up (IQR) for LD 8.4 
(6.0 to 11.3) years & THIN 5.3 (2.5 to 8.5) years. In up to 15 years follow-up no end stage renal 
disease (ESRD) was observed in LD versus 17 in THIN (P=0.01). Eight LD had eGFR<30 versus 
91 in THIN (P<0.001), but no statistically significant difference in adjusted logistic regression 
analyses. Risk of diabetes, depression and cardiovascular disease was significantly higher for 
THIN cohort in adjusted analyses. The risk of hypertension was higher for LD at 5 years, but 
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was not significantly different in fully adjusted analyses at 10 & 15 years. There were 68 deaths 
in LD and 826 in THIN over the follow-up period, with significant difference in mortality favouring 
LD (P<0.001).  
Conclusions: The long-term morbidity and mortality outcomes of LD in comparison with a 
healthy cohort suggest that live donation is safe, with no increased risk of mortality, ESRD or 




Living kidney donation has significantly improved recipient and graft survival worldwide(1). With 
a move to increase the number of living kidney donors further, it is important to have a better 
understanding of the short and long-term outcomes and risks of kidney donation.  
Glomerular filtration rate both estimated and measured GFR (mGFR) have been shown to 
increase with time following donation for some years before deteriorating in the longer-term (2-
4). Some studies have shown that survival and the risk of end stage renal disease (ESRD) is 
similar to those in the general population (5-9), while others have raised significant concerns 
(10-13). 
A recent meta-analysis and two studies suggested that kidney donors have higher blood 
pressure (13-15). However, in other studies, blood pressure differences were not statistically 
significant, comparing donors and controls or hypertensive versus normotensive donors(16,17). 
A tool developed in North America, incorporating multiple health characteristics, to estimate the 
projected risk of ESRD in living kidney donors, produced risk projections higher in the presence 
of a lower eGFR, higher albuminuria, hypertension, current or former smoking, diabetes, and 
obesity (18). 
This is the first long-term comparative study of live kidney donor outcomes in the UK. The aim 
of the study was to investigatethe long term outcomes of UK live kidney donors and to compare 
the outcomes with a cohort of healthy non-donors. In addition, to see if there was a difference 
in the outcomes from other studies as lifelong live donor follow up in the U.K is considered best 
practice by the British Transplantation Society (BTS) (19). 




Ethics:National Health Service Blood and Transplant, Organ Donation and Transplant, (NHSBT) 
UK obtains informed consent from all patients undergoing a transplant and  live donors in the 
UK for continuing data collection and subsequent analyses. The study protocol was approved 
by the UK Renal Registry projects advisory group before the live donor cohort dataset was 
released. For the comparative healthy cohort, ethics approval was already in place to accrue 
data from patients registered in UK general practices (NHS South-East Multicentre Research 
Ethics Committee, 2003). The study protocol was reviewed and approved by an independent 
scientific review committee (reference 16THIN033).  
 
Cohorts for Study: 
Live Donors (LD) dataset: The  dataset obtained from the UK Transplant registry held by 
NHSBT, included all live kidney donors from 1stJanuary 2001 to 31stDecember 2013, with a final 
follow-up end date of 31st  December 2016 .  Data collected for LD cohort comprised:  
 Baseline characteristics 
 Operative procedures and outcomes 
 Follow up data for years 1, 2, 5,10 and 15 
 All-cause mortality 
 Longer term morbidity follow-up data including hypertension, eGFR, proteinuria, 
incident cardiovascular disease (CVD), depression and diabetes. 
 
Comparative Non-donor Cohort dataset: The Health Improvement Network (THIN) database is 
a large UK general practice database which contains anonymized longitudinal patient records 
from over 500 practices, which is equivalent to about 6% of the UK population. The year of entry 
meant the presence of a valid record on the THIN database in the specific year, not necessarily 
a new entry on the database. Data from THIN were stratified by age, sex and year of cohort 
entry to reflect the LD cohort and included baseline characteristics, mortality and morbidity 
outcomes.THIN patients were selected to produce a healthy comparison cohort. Patients with 
the following baseline charateristics contraindicative to live kidney donation were excluded from 
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cohort selection: 
 Less than 18 years of age 
 Hypertension treated with 3 or more medications OR with Left Ventricular hypertrophy 
(LVH) 
 Diabetes (DM) Type1 and 2 
 Current or previous history of malignancy  
 CVD including ischaemic heart disease (IHD), myocardial infarction (MI), unstable 
angina, coronary angioplasty or coronary artery bypass surgery (CABG) 
 Peripheral vascular disease 
 Chronic disease comprising chronic lung disease, chronic liver disease, chronic 
rheumatoid arthritis, lymphoma, myelofibrosis, proteinuria (ACR > 30 mg/mmol or PCR 
> 150 mg/mmol) and eGFR <30 ml/min/1.73m2). 
 
Statistical Methods: 
Analyses of LD cohort included estimation and comparison of incident events, with 95% 
confidence intervals. Student's t-test was employed for comparison of continuous variables 
where appropriate, with use of non-parametric testing as needed and comparison of categorical 
variables used chi-squared tests. Kaplan Meier survival analysis, logistic regression modelling 
and Cox proportional hazards (PH) modelling were used for investigation of co-morbidities and 
all cause mortality. 
Similar statistical methods were employed to compare baseline characteristics between the 
living donors and comparison cohort. Outcomes including mortality and co-morbidities were 
assessed using logistic regression, with Kaplan Meier survival analyses and Cox PH modelling 
as appropriate. For unadjusted survival analyses, all patients had a survival time, either to death 
or censoring; all were included in analyses. In adjusted analyses, where variables with missing 
values were used, analyses included only patients with valid data for all model variables; others 
were excluded. However, mortality and morbidity analyses were repeated using imputations for 
missing values in the strict LTF criteria for LD and restricted THIN cohort comparisons. Variables 
to be included in multivariable modelling comprised age and gender plus characteristics with 
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differences between the 2 cohorts and competing outcomes of interest, including morbidity, end 
stage renal disease or eGFR and year of entry into the cohort. Co-linearity was assessed for 
logistic models examining condition indices, with results >30 indicating unacceptable levels. In 
Cox PH models, proportionality of hazards assumption was assessed using the R routine 
‘Cox.Zph’; overall and individual variable estimates were examined. 
 
Longer-term outcomes, including all-cause mortality, incidence of cardiovascular events, new 
onset hypertension, depression, diabetes mellitus, ESRD, proteinuria and changes in eGFR at 
follow-up years 1, 2, 5, 10 and 15 were analysed.  
The analyses were repeated with most extreme "lost to follow-up" (LTF) definition for live donors, 
where any donor with no valid new data at one of the defined time points was considered LTF 
and the previous time point was taken as the last known time.  The following ‘baseline’ exclusion 
criteria for THIN were applied: GFR measurement <60 ml/min/1.73m2 (Note: any subsequent 
measurement GFR>60 ml/min/1.73m2 invalidated this exclusion and person was included); BMI 
>35.0 kg/m2; current smoker; hypertension recorded as pre-existing condition; urine ACR >30 




LD vs. THIN analyses: 
Table 1 shows comparative baseline characteristics and comorbidities between the LD and 
restricted THIN dataset. The median follow up  (IQR) for LD is 8.4 (6.0 to 11.3) years and for 
THIN is 5.3 (2.5 to 8.5) years. Comparative baseline characteristics of original THIN & LD are 
shown in Table S1. 
 
1. Changes in GFR: 
LD Patients had measured GFRs (mGFR)for 95% and eGFR for 5% at baseline and only eGFRs 
in the follow-up period. THIN had eGFRs throughout the study period. There is a difference of 
20 to 25 mls between the corresponding mGFR and eGFR. Differences in absolute mean GFRs 
between cohorts were statistically significant at all time points and changes in eGFR were also 
significant except for Year 15 (Figure 1A, 1B). In the LD there was an average decline in GFR 
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of 35 mls/min/1.73m2  (eGFR at 1 year – baseline mGFR) over the first year post donation, with 
eGFR increasing steadily thereafter up to 10 years post, followed by a slow decline. In the THIN 
cohort, there was a steady decrease in the eGFR of about 0.33 mls every year. The pattern of 
changing eGFR over time was consistent across age bands in both cohorts (Figures1C, 1D).  
Individual paired changes from the same patients in both the cohorts are shown in Figure 2. 
 
2.   All-cause Mortality: 
There were a total of 894 deaths over the follow-up period, 68 (0.7%) in LD and 826 (3.06%) in 
THIN. For LD, strict LTF criteria were used. Some models included imputations for missing 
values. The data was analysed using original THIN cohort (Table S2) and then reanalysed using 
restricted THIN (Table 2 & Figure 3 A –D). The results were similar in all analyses. Cox PH 
modelling was used to assess mortality at 5, 10 and up to 15 years of follow-up; the hazard ratio 
(HR) was significantly higher (P<0.001) for the THIN group in all models with adjustment for 
potentially confounding factors. Crude mortality rates per 10000 person years for LD and THIN 
for each year of the study was plotted and UK mortality rates reference plot added (Figure 3E). 
 
Cumulative numbers of deaths per year and average incidence per 100000 patient years is 
shown in Table S3.  Analysis of cumulative number of deaths at the follow up periods according 
to age bands, showed that there was no difference between LD and THIN in 18-29 years age 
group, but there were very few deaths observed in this age group in both cohorts as shown in 
Table S4.  There were significantly more deaths in the THIN cohort i) in age groups 30-44, at 
Year 10 (p= 0.020) and all years (p=0.012); ii) in age groups 45-59, at year 5 (P=0.001), year 
10(P<0.001) and all years mortality(P<0.001). In the 60+ group, significant differences in 
mortality between cohorts were seen at all follow-up times and follow-up years (P<0.001). 
Cancer was the major cause of death in both the cohorts. However, as only 19% data was 
available for THIN, no formal comparative analyses were  conducted. 
3. Morbidity Outcomes: 
Comparative 5, 10 and up to 15-year multiple regression morbidity outcomes between LD and 
THIN are shown in Table S5. LTF censored LD vs. restricted THIN, including analysis using 
imputations for missing values is shown in Table 3; year of cohort entry exhibited high co-
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linearity with the intercept and was excluded from models. Risk of diabetes and depression was 
significantly higher for the THIN cohort in all analyses including adjusted models. CVD risk was 
higher for THIN, and was statistically significant in fully adjusted models at 5 and 15 years. The 
risk of hypertension was higher for LD at 5 years, but there was no statistically significant 
difference in fully adjusted analyses at 10 & 15 years. There was no LD with 
eGFR<30ml/min/1.73m2 at 15 years follow-up. There was significantly more proteinuria in LD 





This is the first registry-based study of live donors in the U.K to study the long term outcomes 
of kidney donation by comparing with healthy non-donors; in the UK lifelong live donor follow up  
is considered best practice by the British Transplantation Society (BTS) (12). The non-donor 
cohort was selected from a large UK general practice database, excluding those with 
contraindications for live kidney donation. The comparator group sampled to reflect the LD 
cohort was also matched for the year of entry.  
 
We analysed long-term outcomes of living kidney donors and observed no increased risk of all-
cause mortality in the LD compared to the healthy control cohort with up to 15 years of follow-
up (median follow up of 8.6 years for LD and 5.4 for THIN). Some studies have previously 
reached similar conclusions, showing survival after living kidney donation including older 
donors, being the same as for similar matched individuals who did not donate (13, 20-23). 
However these studies did not have a longitudinal comparative cohort with matched year of 
entry. The statistically significant differences in all-cause mortality in our study were generally 
quite large, with the LD doing better. There were statistically significant differences in ‘all years’ 
mortality in all age groups, with greater mortality in THIN when compared to LD, except 18-29, 
where there was no difference with very small numbers in both cohorts. The older the age group, 
the less years of follow-up needed for emergence of significant differences in mortality. This is 
similar to a published review of evidence which claimed  that the risk of the primary outcome of 
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death was lower in donors than in non-donors  and that the older age group were associated 
with a higher risk of death in both donors and non-donors (24). 
 
Similarly, our study did not any show increase in comorbidities including ESRD in LD when 
compared to THIN. This was true for analyses of eGFR<30 and eGFR<15. To adjust for potential 
confounding factors, comorbidities were used as covariates in multivariable Cox PH and logistic 
regression analyses. Similar results were seen in all analyses, comparing LTF censored LD 
versus restricted THIN and in the full cohorts.   
Other groups have reported findings contradictory to ours (10-13). They have shown that donor 
nephrectomy appears to increase the risk of end-stage renal disease (ESRD), when compared 
with healthy controls, although the absolute risk remains low. A study showed that donors of 
African origin are substantially at a higher risk than Caucasians (10). Our study had 
predominantly (>85%) Caucasian donors. Also, another study showed that 0.47% donors 
developed ESRD with a median time of 18.7 years (11). Thus it is possible that as our cohort 
had a median follow up of 8.4 years, there was insufficient time to observe any ESRD. 
Nevertheless, BTS guidelines recommends lifelong follow up of live donors in the U.K. Thus, it 
is possible that early diagnosis and intervention is contributing to the difference in the outcome. 
 
DM and depression were significantly higher in our healthy cohort in all analyses including fully 
adjusted models at all follow-up periods (p<0.001), which is consistent with a recent review (25). 
CVD was higher in THIN at all follow-up periods but differences were not always statistically 
significant   in fully adjusted analyses. Another study has reported lower incidence of CVD in 
donors in comparison to healthy cohort (24).  Risk of hypertension was generally significantly 
higher in LD, but not in fully adjusted model for 15 years follow-up, This is possibly due to earlier 
detection and management of hypertension, which could have mitigated the long-term risk. A 
recent study of predominantly white donors found that hypertension was common after donation, 
though well controlled in most donors and also showed that use of angiotensin-converting 
enzyme inhibitors or angiotensin receptor blockers was associated with a lower risk for 
developing eGFR<45 and ESRD (26).  
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Our study showed that from one-year post-donation eGFR level improves slowly for 10 years in 
LD.  Thereafter eGFR decreases slowly, similar to the THIN cohort at 15 years. Though, some 
studies (2,3,27) have observed this, this is the largest up to 15-year follow up study to show this 
trend.  
 
Overall, LD group seemed to do better than THIN. This may be partly explained by healthy life-
style, regular follow-up, and early detection and intervention of the LDs as opposed to the THIN 
cohort. As depression was significantly lower in LD, it could be speculated that the LD group 
was more positive and motivated, again possibly contributing to the better long-term health 
outcomes.  In the UK, NHS health care is free at point of access;  most live kidney donors are  
followed up regularly because of the BTS guidelines and such regular consultations facilitate 
donors  access to  early intervention if required. 
 
Strengths and Limitations 
 
Major strength of our study is the sizable donor data combined with a large comparative healthy 
cohort. However as it was a registry-based study, though we had considerable numbers, data 
were not available at all time points for all cohort members. To compensate for this, we 
reanalysed the data, using a stringent LTF definition, where LD with new valid data available at 
each time point were included and others were considered censored at the last new observation. 
We also repeated some analyses using imputation of missing data and the results were 
consistent. However, it should be noted that new data for donors may not have been recorded 
due to the prevailing normal health of the individuals.  Thus, excluding this group could also 
potentially introduce a bias.  
 
Though the comparative THIN cohort were sampled to reflect the LD cohort, there were some 
differences at baseline due to large numbers emphasising small differences. We acknowledge 
that this could have introduced a selection bias. We repeated analyses using the full THIN cohort 
and using further strict exclusion criteria at baseline (restricted THIN). In addition, we compared 
the yearly mortality rates for both LD and restricted THIN with the general population of U.K. 
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The mortality rates were much less for the THIN and LD than the general population of U.K. 
This confirms that the study cohorts were well matched, and that the THIN group were also 
healthier than the average general population.  
 
The consistent message in all the analyses was that the LD group were not disadvantaged in 
comparison to the THIN cohort and that live kidney donation seemed safe. A study looking at adherence 
to healthy lifestyle or interaction with formal health services would perhaps enable us to understand the 
difference in outcomes between the donors and matched non-donor cohort. The gold standard evidence 
to promote or denounce living donation would be from a large randomized live donor study. However, 
ethical and practical considerations make such a study unlikely. Cohort analyses provide robust 
evidence of comparability of outcomes. Sustaining and improving registry data reporting is an essential 




The long-term morbidity and mortality outcomes of live donors in comparison with a healthy 
cohort suggest that live donation is safe, with no increased risk of mortality, ESRD or morbidity 
in up to 15 years follow-up. This could be due to healthy lifestyle, regular long-term follow up, 
early detection and medical intervention in donors, suggesting that promotion of live kidney 
donation is appropriate provided that long term regular monitoring, alongside high quality 
medical care can be guaranteed for donors. 
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Donors  
Adjusted for: 
Gender (Male vs. 
Female) &  Age 
 
 











Model 3  
THIN cohort vs. Live 
Donors  


















3.44 (2.50, 4.73) 
 
<0.001 
Model 4  
THIN cohort vs. Live 
Donors  
Age* 














2.00 (1.26, 3.17) 
 
1.14 (1.12, 1.16) 
1.80 (1.28, 2.54) 
0.97 (0.92, 1.01) 
0.63 (0.15, 2.62) 
1.71 (0.95, 3.08) 
1.61 (0.92, 2.84) 
1.25 (0.51, 3.10) 
0.65 (0.45, 0.93) 
1.02 (1.01, 1.03) 
3.12 (0.41, 23.41) 
1.03 (0.97, 1.08) 
 
1.26 (0.88, 1.81) 



















3.45 (2.40, 4.96) 
 
1.13 (1.12, 1.15) 
1.43 (1.13, 1.82) 
0.99 (0.95, 1.02) 
0.81 (0.29, 2.23) 
1.32 (0.90, 1.95) 
1.03 (0.69, 1.55) 
1.20 (0.73, 1.96) 
0.64 (0.50, 0.82) 
1.01 (1.01, 1.02) 
3.21 (1.43, 7.25) 
1.04 (0.99, 1.08) 
 
1.21 (0.93, 1.57) 



















3.87 (2.71, 5.55) 
 
1.14 (1.12, 1.15) 
1.38 (1.10, 1.74) 
1.00 (0.97, 1.03) 
1.02 (0.44, 2.37) 
1.35 (0.94, 1.95) 
1.10 (0.76, 1.59) 
1.30 (0.82, 2.06) 
0.50 (0.39, 0.65) 
1.01 (1.00, 1.02) 
3.51 (1.73, 7.12) 
1.03 (0.99, 1.08) 
 
1.27 (1.00, 1.63) 


















Model 5 #*# 
THIN cohort vs. Live 
Donors  
Age* 













2.02 (1.37, 2.99) 
 
1.14 (1.12, 1.15) 
1.36 (1.08, 1.72) 
0.99 (0.95, 1.02) 
0.91 (0.28, 2.95) 
1.39 (0.92, 2.10) 
2.05 (1.39, 3.02) 
1.29 (0.70, 2.38) 
0.54 (0.41, 0.71) 
1.02 (1.01, 1.03) 
4.45 (1.05, 18.85) 
0.96 (0.93, 0.99) 
 


















3.33 (2.42, 4.59) 
 
1.13 (1.12, 1.14) 
1.23 (1.03, 1.48) 
1.00 (0.97, 1.03) 
0.97 (0.39, 2.41) 
1.40 (1.05, 1.86) 
1.28 (0.95, 1.73) 
1.19 (0.81, 1.76) 
0.60 (0.49, 0.72) 
1.01 (1.01, 1.02) 
3.62 (1.93, 6.80) 
0.96 (0.94, 0.99) 
 


















3.96 (2.90, 5.41) 
 
1.14 (1.13, 1.15) 
1.21 (1.02, 1.44) 
1.01 (0.99, 1.04) 
1.09 (0.50, 2.38) 
1.31 (1.00, 1.72) 
1.26 (0.96, 1.67) 
1.32 (0.93, 1.89) 
0.49 (0.40, 0.59) 
1.01 (1.00, 1.02) 
3.45 (1.99, 5.99) 
0.96 (0.93, 0.99) 
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*Per year, which equates to about HR of 3.7 for 10 years; **Per unit BMI, equates to HR approximately 0.85 for 5 point increase in BMI;  
§Mean eGFR over  time (5, 10 or all years as appropriate); §§eGFR<30 (i.e. CKD stage 4/5, Yes vs. No, up to the end of the appropriate time 
period. 
 
#*# Model 5 includes imputation for BMI - all missing BMI replaced with grand mean BMI 26.01; Mean GFR -all missing mean GFR 
replaced with GFR=90; Smoking - all missing replaced with never smoker.  
 
Numbers included in models and missing data: 
 
5 years survival: 
Model 1  N=28821, 303 deaths (no missing values) 
Model 2  N=28821, 303 deaths (no missing values) 
Model 3    N=16472, 152 deaths (10515 GFR missing, 5305 BMI Missing) 
Model 4     N=15734, 147 deaths (10515 GFR missing, 5305 BMI Missing, 3310 smoking status missing) 
Model 5  N=28821, 303  deaths (missing values replaced by imputed) 
 
10 years survival: 
Model 1  N=28821, 507 deaths (no missing values) 
Model 2  N=28821, 507 deaths (no missing values) 
Model 3 N=17959, 299 deaths (8463 GFR missing, 5305 BMI Missing) 
Model 4 N=17177, 290 deaths (8463 GFR missing, 5305 BMI Missing, 3310 smoking status missing) 
Model 5  N=28821, 507 deaths (missing values replaced by imputed) 
 
Up to 15 years: 
Model 1  N=28821, 553 deaths (no missing values) 
Model 2  N=28821, 553 deaths (no missing values) 
Model 3 N=18159, 320 deaths (8175 GFR missing, 5305 BMI Missing) 
Model 4 N=17368, 311 deaths (8175 GFR missing, 5305 BMI Missing, 3310 smoking status missing) 


























  5 years follow-up 
 




Model - variables OR (95% ci)  P-value OR (95% ci) P-
value 






1 THIN vs. LD 
 
2 THIN vs. LD 
 
0.49 (0.17, 1.42) 
 
0.22 (0.07, 0.70) 
 
  0.188 
 
  0.010 
 
3.44 (0.45, 26.33) 
 
2.11 (0.27, 16.58) 
 
  0.234 
 








2.51 (1.23, 5.14) 0.012 2.30 (1.26, 4.19) 0.006 2.12 (1.19, 3.79) 0.011 




    M vs. F        
    Age (year) 
 
3 THIN vs. LD 
    M vs. F 
    Age (year) 
    BMI (baseline) 
    Hypertension 
    CVD 
    DM 
    Depression 
    Smoking (Y)  
0.89 (0.31, 2.59) 
1.18 (1.11, 1.26) 
 
0.61 (0.36, 1.04) 
0.65 (0.41, 1.05) 
1.17 (1.14, 1.20) 
1.24 (1.18, 1.31) 
0.26 (0.16, 0.43) 
0.09 (0.00, 1.81) 
0.11 (0.00, 3.12) 
0.49 (0.14, 1.64) 
1.73 (1.08, 2.77) 
 
  0.836 
<0.001 
 







  0.116 
  0.196 
  0.245 
  0.022 
 
1.43 (0.49, 4.15) 
1.18 (1.10, 1.26) 
 
2.06 (0.73, 5.81) 
1.35 (0.70, 2.59) 
1.15 (1.11, 1.19) 
0.97 (0.88, 1.07) 
1.14 (0.46, 2.83) 
0.05 (0.00, 1.13) 
1.93 (0.71, 5.21) 
1.05 (0.37, 3.04) 
2.66 (1.39, 5.07) 
 
  0.515 
<0.001 
 
  0.172 
  0.372 
<0.001 




  0.060 
  0.197 
  0.923  




assigned   
OR 
BP>140/90) 
1 THIN vs. LD 
 
2 THIN vs. LD 
    M vs. F 
   Age (year) 
 
3 THIN vs. LD 
    M vs. F 
    Age (year) 
    BMI (baseline)        
    CVD 
    DM 
    Depression 
eGFR<30 
    Smoking (Y)  
 
0.64 (0.59, 0.69) 
 
0.60 (0.56, 0.65) 
1.06 (0.99, 1.14) 
1.04 (1.04, 1.04) 
 
0.66 (0.61, 0.73) 
1.06 (0.98, 1.15) 
1.03 (1.03, 1.04) 
1.07 (1.06, 1.08) 
1.52 (1.15, 2.01) 
1.43 (1.04, 1.96) 
1.17 (0.99, 1.39) 
0.62 (0.19, 1.97) 









  0.156 
<0.001 
<0.001 
  0.003 
  0.029 
  0.061 
  0.414 
  0.521 
 
0.82 (0.72, 0.94) 
 
0.81 (0.71, 0.93) 
1.03 (0.92, 1.16) 
1.03 (1.03, 1.04) 
 
0.86 (0.73, 1.00) 
1.03 (0.90, 1.18) 
1.03 (1.02, 1.03) 
1.06 (1.04, 1.08) 
0.98 (0.70, 1.38) 
1.15 (0.80, 1.67) 
1.03 (0.83, 1.28) 
0.97 (0.29, 3.26) 
1.14 (0.97, 1.34) 
 
  0.004 
 
  0.003 
  0.575 
<0.001 
 
  0.048 
  0.698 
<0.001 
<0.001 
  0.929 
  0.447 
  0.771 
  0.966 
  0.101   
 
0.82 (0.67, 0.99) 
 
0.83 (0.68, 1.01) 
0.93 (0.77, 1.11) 
1.03 (1.02, 1.03) 
 
0.89 (0.71, 1.13) 
0.91 (0.72, 1.13) 
1.02 (1.01, 1.03) 
1.05 (1.02, 1.09) 
1.19 (0.71, 1.99) 
1.60 (0.87, 2.94) 
0.98 (0.69, 1.38) 
# 
1.02 (0.79, 1.32) 
 
  0.040 
 
  0.067 
  0.412 
<0.001 
 
  0.333 
  0.387 
  0.002 
  0.001 
  0.509  
  0.129 
  0.894 
  # 
  0.854 
Diabetes 
 
1 THIN vs. LD 
 
2 THIN vs. LD 
    M vs. F 
   Age (year) 
 
3 THIN vs. LD 
    M vs. F 
   Age (year) 
   BMI (baseline) 
   Hypertension 
   CVD 
   Depression 
eGFR<30 
   Smoking (Y)  
3.43 (2.18, 5.39) 
 
3.04 (1.93, 4.78) 
2.10 (1.58, 2.80) 
1.05 (1.04, 1.06) 
 
4.20 (2.52, 6.98) 
2.08 (1.49, 2.90) 
1.03 (1.01, 1.04) 
1.17 (1.13, 1.21) 
3.84 (2.43, 6.08) 
1.15 (0.55, 2.43) 
1.91 (1.17, 3.13) 
- 













  0.712 
  0.010 
  - 
  0.161 
 
2.36 (1.46, 3.81) 
 
2.16 (1.33, 3.50) 
1.65 (1.22, 2.23) 
1.05 (1.04, 1.06) 
 
3.31 (1.81, 6.06) 
1.51 (1.03, 2.22) 
1.02 (1.00, 1.04) 
1.21 (1.15, 1.27) 
6.93 (2.95, 16.29) 
1.29 (0.65, 2.55) 
1.18 (0.68, 2.05) 
1.31 (0.15, 11.14) 




  0.002 




  0.033 
  0.013 
<0.001 
<0.001 
  0.461 
  0.566 
  0.803 
  0.026 
 
2.94 (1.58, 5.44) 
 
2.86 (1.54, 5.32) 
1.33 (0.86, 2.06) 
1.05 (1.03, 1.07) 
 
4.09 (1.77, 9.48) 
1.15 (0.63, 2.08) 
1.03 (1.00, 1.06) 
1.23 (1.13, 1.34) 
5.90 (1.38, 25.19) 
1.15 (0.44, 3.02) 
1.20 (0.52, 2.77) 
# 
1.56 (0.83, 2.92) 
 
  0.001 
 
  0.001 
  0.198 
<0.001 
 
  0.001 
  0.656 
  0.046 
<0.001 
  0.017 
  0.777 
  0.678 
 # 




1 THIN vs. LD 
 
2 THIN vs. LD 
    M vs. F  
   Age (year) 
 
3.THIN vs. LD 
    M vs. F 
    Age (year) 
    BMI (baseline)    
    Hypertension 
    Diabetes 
    Depression 
eGFR<30 
    Smoking (Y)  
 
2.09 (1.50, 2.92) 
 
1.64 (1.17, 2.31) 
1.82 (1.41, 2.34) 
1.09 (1.07, 1.10) 
 
1.63 (1.13, 2.35) 
1.74 (1.31, 2.31) 
1.07 (1.06, 1.08) 
0.99 (0.95, 1.03) 
2.95 (2.01, 4.33) 
1.13 (0.53, 2.39) 
2.31 (1.51, 3.54) 
- 
1.54 (1.16, 2.05) 
<0.001 
 




  0.008 
<0.001 
<0.001 
  0.675 
<0.001 
  0.753 
<0.001 
  - 
  0.003 
1.70 (1.13, 2.55) 
 
1.40 (0.93, 2.12) 
2.18 (1.61, 2.94) 
1.09 (1.07, 1.10) 
 
1.19 (0.75, 1.89) 
2.08 (1.46, 2.96) 
1.08 (1.06, 1.09) 
0.99 (0.94, 1.04) 
2.21 (1.31, 3.70) 
1.17 (0.59, 2.31) 
2.86 (1.84, 4.45) 
- 
1.58 (1.11, 2.26) 
  0.010 
 




  0.451 
<0.001 
<0.001 
  0.617 
  0.003 
  0.658 
<0.001 
  - 
  0.012 
2.43 (1.39, 4.26) 
 
2.20 (1.24, 3.90) 
2.46 (1.56, 3.86) 
1.09 (1.07, 1.12) 
 
2.00 (1.02, 3.94) 
2.21 (1.30, 3.76) 
1.09 (1.06, 1.12) 
1.03 (0.96, 1.11) 
2.89 (1.11, 7.51) 
1.13 (0.43, 2.97) 
3.27 (1.70, 6.28) 
# 
1.44 (0.83, 2.50) 
  0.002 
 




  0.045 
  0.004 
<0.001 
  0.437 
  0.030 
  0.800 
<0.001 
 # 
  0.192 
Depression 
 
1 THIN vs. LD 
 
2 THIN vs. LD 
    M vs. F 
   Age (year) 
 
3 THIN vs. LD 
    M vs. F 
    Age (year) 
    BMI (baseline)     
    Hypertension 
    CVD 
9.55 (6.97, 13.08) 
 
10.03 (7.32, 13.75) 
  0.50 (0.44, 0.58) 
  0.99 (0.98, 0.99) 
 
11.30 (8.02, 15.93) 
  0.50 (0.43, 0.59) 
  0.98 (0.97, 0.99) 
  1.01 (0.99, 1.03) 
  1.08 (0.91, 1.28) 










  0.262 
  0.362 
<0.001 
9.65 (6.01, 15.50) 
 
10.19 (6.34, 16.39) 
  0.57 (0.48, 0.68) 
  0.98 (0.97, 0.99) 
 
12.40 (7.21, 21.31) 
  0.56 (0.45, 0.71) 
  0.97 (0.96, 0.98) 
  1.01 (0.98, 1.04) 
  1.00 (0.79, 1.28) 










  0.419 
  0.981 
<0.001 
11.93 (6.28, 22.66) 
 
12.46 (6.55, 23.70) 
  0.60 (0.45, 0.80) 
  0.98 (0.97, 0.99) 
 
16.96 (7.83, 36.73) 
  0.54 (0.37, 0.79) 
  0.97 (0.95, 0.98) 
  1.03 (0.98, 1.08) 
  0.85 (0.56, 1.27) 





  0.002 
 
<0.001 
  0.001 
<0.001 
  0.223 
  0.422 
<0.001 
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    Diabetes 
eGFR<30 
    Smoking (Y)  
 
  1.87 (1.15, 3.05) 
  - 
  1.35 (1.14, 1.60) 
 
  0.012 
  - 
  0.001 
 
  1.17 (0.67, 2.02) 
  1.13 (0.14, 9.02) 
  1.48 (1.16, 1.89) 
 
  0.581 
  0.911 
  0.001 
 
  1.08 (0.47, 2.46) 
# 
  1.23 (0.82, 1.85) 
 
  0.856 
 # 
  0.319 
 
 
# No Live Donors with eGFR<30ml/min/1.73m2 at 15 years follow-up. 
 
Numbers in analysis and missings: 
5 years analyses 
Maximum LD (4165) and THIN (15866): THIN reduced by stringent cohort selection, LD have had LTF applied. 
All cases LD 4165, THIN 11304 = maximum 15469 observations.  
All outcomes have same missings as BMI and smoking status based on baseline measurement only. 
Model 1 - 15469 observations, 14 outcomes, no missing data. 
Model 2 - 15469 observations, 14 outcomes, no missing data. 
Model 3 - 11824 observations, 12 outcomes. Missing 3645: 3267 BMI, 2021 Smoking status. 
 
10 years analyses: 
Maximum LD (1095) and THIN (5702): THIN reduced by stringent cohort selection, LD have had LTF applied. 
All cases LD 1095, THIN 4147 = maximum 5242 observations.  
All outcomes have same missings as BMI and smoking status based on baseline measurement only. 
Model 1 - 5242 observations, 14 outcomes, no missing data. 
Model 2 - 5242 observations, 14 outcomes, no missing data. 
Model 3 -  3727 observations, 11 outcomes. Missing  1515: 1367 BMI, 967 Smoking status. 
 
Up to 15 years analyses: 
Maximum LD (595) and THIN (1334): THIN reduced by stringent cohort selection, LD have had LTF applied. 
All cases LD 595, THIN 1334 = maximum 1929 observations.  
CKD (GFR<30) - too few observations, no analyses. 
All outcomes have same missings as BMI and smoking status based on baseline measurement only. 
Model 1 - 1929 observations, 1279 outcomes, no missing data. 
Model 2 - 1929 observations, 1279 outcomes, no missing data. 
























Figure 1: Changes in GFR: A) Over 15 year period in Live Donor and THIN Cohorts, both mean and 
paired differences form the same patients; B) Overall GFR changes over time by cohort; C) 
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B                                  GFR decline by Cohort     



































       Panel A:  
 Cohort median comparisons statistically significant, Mann-Whitney U-test P<0.001. 
Panel B & D 
 LD Patients had measured GFRs at baseline (mGFR) and eGFRs in the follow-up period. 
There is a difference of 20 to 25 mls between the corresponding mGFR and eGFR. THIN had 










































Changes are estimated as time period measure - previous time period measure divided by number of years for individual cohort member. All 
included in any plot have both measures needed to generate the difference, so these are paired (within individual differences) not just 
comparing mean for LD cohort vs. THIN. 
 







Figure 3: Mortality plots 
 
A) All Live Donors vs. THIN B) LTF censored Live Donors vs. THIN C) All Live Donors vs. 
Restricted THIN D) LTF censored Live Donors vs. Restricted THIN. (Figures A-D Log Rank test 
P<0.001).  
E) Yearly Mortality Rates of All Live Donors & Restricted THIN in comparison with Yearly 







































LD vs THIN mortality rates per 10000 person years with UK reference 
line
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